Quality of life in MAP.3 (Mammary Prevention 3): A randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 14, 2014, Pages 1427-1436

  Maunsell, Elizabeth ^a   Goss, Paul E ^j   Chlebowski, Rowan T ^k   Ingle, James N ^l   Alés Martínez, José E ^m   Sarto, Gloria E ^o   Fabian, Carol J ^p   Pujol, Pascal ^q   Ruiz, Amparao ⁿ   Cooke, Andrew L ^c   Hendrix, Susan ^r   Thayer, Debra W ^s   Rowland, Kendrith M ^t   Dubé, Pierre ^b   Spadafora, Silvana ^d   Pruthi, Sandhya ^l   Lickley, Lavina ^e   Ellard, Susan L ⁱ   Cheung, Angela M ^f   Wactawski Wende, Jean ^u   Gelmon, Karen A ⁱ   Johnston, Dianne ^g   Hiltz, Andrea ^g   Brundage, Michael ^g   Pater, Joseph L ^h   Tu, Dongsheng ^g   Richardson, Harriet ^g   more..

^a Université Laval   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c CANCERCARE MANITOBA   (Canada)

^d Algoma District Cancer Program   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g National Cancer Institute of Canada Clinical Trials Group   (Canada)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l MAYO CLINIC   (United States)

^m HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

ⁿ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^o UNIVERSITY OF WISCONSIN MADISON   (United States)

^p UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^q HÔPITAL ARNAUD DE VILLENEUVE   (France)

^r Hutzel Womens Hospital   (United States)

^s MEDSTAR RESEARCH INSTITUTE   (United States)

^t Carle Cancer Center/Mills Breast Cancer Institute   (United States)

^u UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; PLACEBO; ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; MULTICENTER STUDY; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SHORT FORM 36; VERY ELDERLY; BREAST TUMOR; CONTROLLED CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84902976096     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.2483     Document Type: Article

References (27)

1. Visvanathan K, Hurley P, Bantug E, et al: Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:2942-2962, 2013
2. Goss PE, Ingle JN, Alés-Martínez JE, et al: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381-2391, 2011
3. Ganz PA: Breast cancer, menopause, and long-term survivorship: Critical issues for the 21st century. Am J Med 118:136-141, 2005
4. Ganz PA, Rowland JH, Desmond K, et al: Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 16:501-514, 1998 (Pubitemid 28135592)
5. Gail MH, Costantino JP, Bryant J, et al: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846, 1999
6. Hilditch JR, Lewis J, Peter A, et al: A menopause-specific quality of life questionnaire: Development and psychometric properties. Maturitas 24:161-175, 1996
7. Ware JE, Kosinski M: SF-36 Physical and Mental Summary Scales: A manual for users of Version 1 (ed 2). Boston, MA, QualityMetric, 2001
8. Ware JE, Kosinski M, Dewey JE: How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI, QualityMetric, 2000
9. Ware JE, Snow KK, Kosinksi M, et al: SF-36 Health Survey Manual and Interpretation Guide. Boston, MA, The Health Institute, 1993
10. Hilditch JR, Lewis J, Ross AH, et al: A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas 24:177-184, 1996
11. Norman GR, Sloan JA, Wyrwich KW: The truly remarkable universality of half a standard deviation: Confirmation through another look. Expert Rev Pharmacoecon Outcomes Res 4:581-585, 2004 (Pubitemid 39359644)
12. Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41:280-287, 2005 (Pubitemid 40126961)
13. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
14. Chlebowski R, Cuzick J, Amakye D, et al: Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 18:S1-S11, 2009
15. Kanematsu M, Morimoto M, Honda J, et al: The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer 11:436, 2011
16. Henry NL, Azzouz F, Desta Z, et al: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936-942, 2012
17. Fallowfield LJ, Kilburn LS, Langridge C, et al: Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106:1062-1067, 2012
18. van Nes JG, Fontein DB, Hille ET, et al: Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: A Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 134:267-276, 2012
19. Visvanathan K, Chlebowski RT, Hurley P, et al: American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258, 2009
20. Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659-2669, 1999 (Pubitemid 29415221)
21. Land SR, Wickerham DL, Costantino JP, et al: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2742-2751, 2006
22. Waters EA, McNeel TS, Stevens WM, et al: Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 134:875-880, 2012
23. Waters EA, Cronin KA, Graubard BI, et al: Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 19:443-446, 2010
24. Hadji P: Breast cancer: Aromatase inhibitors - Bone health assessment is crucial. Nat Rev Clin Oncol 9:254-255, 2012
25. Coleman RE, Banks LM, Girgis SI, et al: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 8:119-127, 2007 (Pubitemid 46158372)
26. Cheung AM, Tile L, Cardew S, et al: Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: A nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 13:275-284, 2012
27. Coleman RE, Banks LM, Girgis SI, et al: Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 124:153-161, 2010